Storage Is No Longer the Cheap Part Storage used to be the line item nobody argued about. A

OpenAI Goes After Industry Verticals OpenAI is steering its models into specialised industries and undercutting open-source rivals on

Durante uma conferência de imprensa em Seul, a OpenAI revelou que está a investigar e a produzir conjuntamente com a Samsung os próximos chips de inferência da empresa, numa altura em que os utilizadores empresariais do ChatGPT na Coreia do Sul cresceram 28 vezes num ano.

The post OpenAI reforça parceria com a Samsung no desenvolvimento de chips de nova geração appeared first on Tek Notícias.

Leading chipmakers Samsung Electronics and Taiwan Semiconductor Manufacturing Co. announced plans to adopt ASML’s latest chipmaking machines in the next several years—and they also joined Intel in agreeing to a crucial technology change that could boost chip production on the new machines by 40 percent.

This signifies the semiconductor industry’s broader embrace of high NA EUV photolithography technology that can cost up to $400 million per machine and is only provided by the Dutch technology company ASML, Bloomberg reports. The technology would allow chip designers to implement even smaller features in potentially more powerful and efficient next-generation chips produced for AI data centers and consumer electronics such as smartphones, tablets, and laptops.

ASML’s EUV (extreme ultraviolet) lithography machines enable chipmakers to use powerful laser light to imprint patterns in silicon wafers, layer by layer, and gradually form the computer circuitry that makes silicon chips work. Compared to older deep ultraviolet lithography, EUV technology harnesses a more powerful source of light with a shorter wavelength to create even smaller features on silicon wafers.

Read full article

Comments

© Michel de Heer | ASML

Leading chipmakers Samsung Electronics and Taiwan Semiconductor Manufacturing Co. announced plans to adopt ASML’s latest chipmaking machines in the next several years—and they also joined Intel in agreeing to a crucial technology change that could boost chip production on the new machines by 40 percent.

This signifies the semiconductor industry’s broader embrace of high NA EUV photolithography technology that can cost up to $400 million per machine and is only provided by the Dutch technology company ASML, Bloomberg reports. The technology would allow chip designers to implement even smaller features in potentially more powerful and efficient next-generation chips produced for AI data centers and consumer electronics such as smartphones, tablets, and laptops.

ASML’s EUV (extreme ultraviolet) lithography machines enable chipmakers to use powerful laser light to imprint patterns in silicon wafers, layer by layer, and gradually form the computer circuitry that makes silicon chips work. Compared to older deep ultraviolet lithography, EUV technology harnesses a more powerful source of light with a shorter wavelength to create even smaller features on silicon wafers.

Read full article

Comments

© Michel de Heer | ASML

Washington imposed sanctions on Inspur because of its work with the Chinese military. But the company’s subsidiary kept shipping Nvidia’s best chips to feed China’s leading A.I. firms.

Data centers have become the largest driver of a surging electricity demand that is straining US power grids. But the AI data center boom has also accelerated investment in a technology that could provide a silver lining for everyone—solid-state power transformers that replace industrial-age technology with modern power electronics.

Power grids currently rely on conventional transformer technology that is painstakingly assembled by hand and has a fundamental design dating back to the 1880s. Two copper wire coils manually wound around a steel core create electromagnetic fields that help step up voltage levels of alternating current electricity for long-distance transmission or step down voltage levels for the electricity use of homes and businesses. The largest power transformers cannot be mass-manufactured but are instead custom-built for each utility company’s electrical substations.

Manufacturing constraints, coupled with the scramble to upgrade US power infrastructure, have meant utility companies and other customers must wait up to several years for delivery of new power transformers. That not only hinders power grid infrastructure expansion needed to support growing electricity demand, but also delays the process of replacing aging power transformers.

Read full article

Comments

© EPRI

Há dois meses, falamos aqui sobre o RetinaDesk, um site muito bacana que ajuda você a escolher o melhor monitor externo para o seu Mac, levando em conta todas as especificidades dos computadores da Apple.

Pois bem, recentemente, a ferramenta ficou ainda mais completa com a adição de uma página que ajuda você a descobrir, de maneira extremamente intuitiva, a quantidade máxima de displays externos suportados pela sua máquina.

O banco de dados da ferramenta cobre todos os Macs com Apple Silicon lançados até hoje, bem como suas respectivas variantes — detalhe que joga o total de computadores listados pelo RetinaDesk para nada menos que 53.

Encontrar essa página é fácil: basta acessar o site do RetinaDesk, clicar na aba “Tools” na parte de cima da tela e, depois, selecionar a opção “Mac External Display Support by Chip” — ou simplesmente acessar esse link. Feito isso, é só selecionar o modelo do seu Mac na seção “Which Mac is it?” e, em seguida, sua respectiva variante — indicada pelo chip e o ano de lançamento (e, às vezes, o número de portas do computador) — em “Step 2”.

Uma vez que você indicar o modelo do seu Mac, o número máximo de monitores externos ao qual ele pode ser conectado deverá aparecer à direita da tela, junto de uma ilustração do seu “setup máximo” — ou seja, com o maior número de monitores possível.

A nova página, no entanto, não para por aí, já que ela também conta com outra seção a qual ajuda você a montar setups com diferentes combinações de monitores, os quais podem ter resoluções e taxas de atualização distintas — sempre levando em conta, é claro, as limitações do seu computador. Ela também é uma boa forma de descobrir se o seu Mac suporta uma resolução ou uma taxa de atualização (ou uma combinação dessas duas coisas) específica.

A seção “What each built-in port can drive”, por sua vez, exibe com quais resoluções/taxas de atualização cada porta do seu computador é compatível, além de revelar a sua versão (se é Thunderbolt 4 ou 5, por exemplo). Logo abaixo, temos a seção “How you can arrange the displays” que, como seu nome indica, mostra todas as combinações possíveis de monitores para a sua máquina.

Por fim, a ferramenta também deixa você comparar um Mac qualquer com outro modelo da sua escolha, checar se sua máquina precisa estar no modo clamshell para suportar um setup específico e aprender sobre soluções alternativas e suas respectivas concessões.

Assim como o resto das ferramentas do RetinaDesk, essa nova página é totalmente gratuita, com o único “porém” sendo o fato de que ela não está disponível em português — problema que, é claro, pode ser facilmente remediado com a ajuda das ferramentas de tradução dos navegadores atuais.

Muito útil, não? 🖥️

Six giant investment firms announced a $500 billion effort to raise money for customers of Nvidia to pay for computing power.

Animal testing has shaped modern drug development for decades, but its limitations become especially visible when scientists evaluate cancer immunotherapies. These treatments are designed to stimulate the immune system to recognize and destroy malignant cells, yet the same powerful immune activation can trigger life-threatening complications in patients. Researchers at the University of Rochester are developing a human-cell-based alternative: miniature tissue models known as organs-on-a-chip that could help predict these toxicities before experimental medicines reach clinical trials.

The work is being led through the university’s Translational Center for Barrier Microphysiological Systems, or TraCe-bMPS. The center is building drug-development tools around modular µSiM tissue chips, devices that contain ultrathin membranes populated with human cells. Unlike conventional laboratory cultures, these systems are engineered to reproduce key features of biological barriers, including the physical separation between tissues, controlled exposure to drugs, and measurable inflammatory responses. Their modular construction also allows the devices to be manufactured in large quantities with consistent dimensions and materials.

The platform is based primarily on acrylic components and incorporates membranes designed to mimic interfaces found in the human body. Such barriers regulate the movement of molecules and immune cells between compartments, making them central to drug absorption, toxicity, and inflammation. By assembling reproducible chips with human cells, researchers can study how a therapy affects a tissue under conditions that more closely approximate human biology than many animal models. The design also makes it possible to modify individual components for different organs or disease settings.

A major feature of the Rochester system is the integration of sensors directly into the chips. Developed in part through the work of biomedical engineering professor Benjamin Miller, these sensors can track barrier function and inflammatory signaling in real time. Instead of waiting until the end of an experiment to examine damaged cells, researchers can observe how a tissue responds as a drug is introduced. Changes in electrical or molecular signals may reveal that a barrier is becoming more permeable or that inflammatory pathways are being activated, providing an early warning of toxicity.

The immediate focus is on two severe complications associated with some cancer immunotherapies. Cytokine release syndrome, commonly called CRS, occurs when activated immune cells release large quantities of signaling proteins known as cytokines. The resulting systemic inflammation can cause fever, low blood pressure, breathing difficulties, and, in the most serious cases, organ failure. Immune effector cell-associated neurotoxicity syndrome, or ICANS, can affect the nervous system, producing confusion, seizures, impaired speech, or other neurological symptoms. Both conditions are difficult to predict reliably with animal testing because species differ in immune signaling networks and cell-surface receptors.

“The goal is to predict these toxicities from human cells on a chip, before a drug ever reaches a patient, and to do it without relying on animal models that have repeatedly failed to predict CRS in people,” says James McGrath, director of TraCe-bMPS and the William R. Kenan Jr. Professor of Biomedical Engineering. The approach does not simply attempt to reproduce a whole human body in miniature. Instead, it focuses on specific biological barriers and immune interactions that are directly relevant to the safety question being studied.

The project has now reached an important regulatory stage. The team was accepted into the US Food and Drug Administration’s Innovative Science and Technology Approaches for New Drugs, or ISTAND, pilot program. ISTAND is intended to help evaluate emerging methods that could improve drug development and eventually support regulatory decisions. Acceptance does not mean that the tissue-chip platform has already been approved for routine use, but it creates a formal pathway for the researchers to work with the FDA on defining the evidence needed for qualification.

The Rochester group is preparing a detailed qualification plan that will describe clinical considerations, timelines, data-sharing procedures, and statistical methods for evaluating the technology. If the platform ultimately receives FDA qualification, pharmaceutical companies could use its results as part of the evidence submitted in support of new drug applications. Such recognition would represent a significant step for organs-on-a-chip research, which has expanded rapidly but has only rarely progressed into formal regulatory programs.

The effort comes as US regulators seek alternatives to animal testing in preclinical safety studies. The FDA Modernization Act 2.0, enacted in 2022, opened the door for non-animal methods, while the agency’s 2025 roadmap outlined further efforts to reduce reliance on animal models. Researchers say pharmaceutical companies are showing strong interest because many immunotherapies are already in clinical development and carry risks of CRS or ICANS. The Rochester team collaborated with Graham Marsh of the Critical Path Institute and consulted with scientists at Pfizer about how the tool could fit into real-world drug development. If successful, the technology could give researchers a more human-relevant way to identify dangerous immune reactions early, helping developers eliminate unsafe candidates and refine promising treatments before patients are exposed.

Subject of Research: Human-cell tissue chips for predicting cancer immunotherapy toxicities.

Web References: University of Rochester; Translational Center for Barrier Microphysiological Systems; University of Rochester Biomedical Engineering; FDA ISTAND pilot program; FDA Modernization Act 2.0.

Image Credits: URochester photo / J. Adam Fenster.

Keywords: Drug discovery, tissue chips, organs-on-a-chip, cancer immunotherapy, cytokine release syndrome, CRS, ICANS, neurotoxicity, animal testing alternatives, biomedical engineering, microphysiological systems, human-cell models.

Com uma queda de 10% no segundo trimestre do ano, o mercado dos tablets recuou pela primeira vez em vários anos, num período que por norma tem muita procura para o regresso às aulas.

The post Mercado dos tablets recua 10%. Fabricantes mudam prioridades e apostam no segmento premium appeared first on Tek Notícias.

As data centers gobble up memory chips, other industries that need the components, including electronics companies like Apple and medical device makers, are asking for government help.

Após quase um ano disponível oficialmente para todos os usuários, o iOS 26 recebeu seu primeiro jailbreak, graças aos desenvolvedores por trás do popular Dopamine (o qual inclui os gerenciadores de pacotes Sileo e Zebra).

O desenvolvedor Lars Fröder, mais conhecido como opa334, lançou o Dopamine 3.0, o qual adiciona suporte a várias versões mais recentes do sistema operacional dos iPhones, incluindo o iOS 26.0 e o iOS 26.0.1 — entretanto, apenas em alguns dispositivos.

Mais precisamente, o jailbreak está disponível em aparelhos com os chips A12 Bionic ou A13 Bionic. Vale lembrar que, em junho, pesquisadores encontraram um bug no controlador desses processadores, o que permitiu modificar estruturas críticas desses chips — viabilizando o desenvolvimento do jailbreak em questão.

Ademais, o Dopamine 3.0 tem suporte a todos os dispositivos que executam o iOS 16.5.1 ao iOS 17.3.1, ampliando significativamente a gama de dispositivos e versões de software compatíveis.

Eis a lista de compatibilidade completa da nova versão:

• A12, A12X, A12Z, A13: iOS 16.6–18.7.1 e iOS 26.0–26.0.1
• A14, M1: iOS 16.6–17.3.1
• A15, A16, A17, M2: iOS 16.5.1–17.3.1
• A10: iOS 15.8.7–15.8.8 e iOS 16.7–18.7.1
• A10X: iOS 15.8.7–15.8.8 e iOS 16.7–17.7.11
• A9, A9X, A11: iOS 15.8.7–16.7.16
• A8, A8X: iOS 15.8.7–15.8.8

É possível baixar e obter mais detalhes do jailbreak na sua página do GitHub.

via MacRumors

Electrical interconnects may very well be the unsung heroes of modern microchips. These tiny wires – typically made

One year after unveiling a first-of-its-kind “microwave brain” microchip capable of computing on ultrafast data and wireless signals,

The Silicon Valley chipmaker’s revenue rose 25 percent in the latest quarter, its fastest growth in 15 years, as A.I. firms increasingly bought chips known as central processing units.

In a major boost to American domestic manufacturing, the Trump Administration today announced that Taiwan Semiconductor Manufacturing Company (TSMC) is committing an additional $100 billion in investments for advanced semiconductor facilities in the United States. This brings TSMC’s total planned investment to $265 billion — one of the largest foreign direct investments in American history.

The announcement, made jointly by the White House and the Department of Commerce, highlights the success of strategic trade and investment partnerships, particularly the historic U.S.-Taiwan deal signed in January 2026. As a direct result, TSMC will build four additional advanced semiconductor manufacturing and packaging facilities, bringing its U.S. footprint to 12 leading-edge facilities, primarily in Arizona.

Building on Momentum

This latest expansion builds on previous commitments. TSMC’s original plans started at around $65 billion, which were later increased. The new infusion underscores sustained momentum under the current administration’s focus on reshoring critical supply chains.

In a statement, U.S. Commerce Secretary Howard Lutnick emphasized the job-creating impact, “President Trump’s leadership is driving companies to invest in American manufacturing. TSMC’s announcement of an additional $100 billion investment following our historic deal on trade and investment with Taiwan will create tens of thousands of American jobs and bring advanced semiconductor manufacturing back to America.”

TSMC Chairman and CEO Dr. C.C. Wei echoed the sentiment, crediting collaboration with the administration and strong U.S. customer demand, “We appreciate the strong collaboration and support of the Trump Administration, Secretary Lutnick and our leading U.S. customers… This is to support the strong multi-year demand from our leading U.S. customers, and we believe this investment will further foster the development of the U.S. semiconductor ecosystem, strengthen the supply chain, and support significant job creation in the United States.”

Economic and Strategic Impact

The investments are expected to generate significant construction and high-tech jobs, along with billions in indirect economic output. Beyond direct facilities, the broader U.S.-Taiwan trade and investment framework is catalyzing an additional $500 billion in Taiwanese investments — $250 billion in direct semiconductor and related enterprises, plus another $250 billion to strengthen the full supply chain in the U.S.

This move addresses long-standing concerns about reliance on overseas production for advanced chips, especially those critical for AI, defense, automotive, and consumer electronics. By expanding domestic capacity with a world-leading foundry like TSMC, the U.S. strengthens its position in the global semiconductor race while creating high-paying opportunities for American workers.

The Trump Administration’s approach, which combines diplomatic deals, incentives for onshoring, and a focus on national security, continues to yield concrete results in rebuilding America’s industrial base.
‎
MacDailyNews Take: With 12 state-of-the-art facilities on track, America is poised to capture a much larger share of advanced chip production. This not only bolsters economic competitiveness, but also enhances supply chain resilience against geopolitical risks.

---

‎
Please help support MacDailyNews — and enjoy subscriber-only articles, comments, chat, and more — by subscribing to our Substack: macdailynews.substack.com. Thank you!

Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.

The post Trump admin secures record $265 billion TSMC investment in U.S. semiconductor manufacturing, adding 4 new facilities for total of 12 appeared first on MacDailyNews.

Apple’s next iPad lineup refresh could begin this fall with a new iPad mini, followed by updates across the rest of the tablet family during 2027. The reported schedule would give Apple a rolling series of launches rather than one event covering every iPad at once.

Bloomberg’s Mark Gurman reports that Apple is preparing replacements for the iPad mini, entry-level iPad, iPad Air and iPad Pro. The compact model is expected to arrive first, potentially as early as October, while the remaining tablets would follow over the next several months.

Apple has not announced any of the devices, and release timing can change. The report nevertheless gives prospective buyers a clearer picture of where each current model sits in its cycle. The first update could also bring one of the most requested display improvements to Apple’s smallest tablet.

iPad Lineup Refresh Starts With the Mini

The iPad lineup refresh is expected to begin with the iPad mini, which has received fewer updates than Apple’s larger tablets. The current design remains popular because it offers an 8.3-inch screen in a device small enough to hold comfortably with one hand, place in a small bag or use as a portable reading and note-taking tool.

The next model is reportedly moving to an OLED display. That would give the iPad mini deeper black levels, stronger contrast and more vivid color than its current LCD panel. OLED would be particularly noticeable when reading in dark environments, watching video or working with images.

The new display is expected to measure approximately 8.4 inches without producing a major change to the overall design. Apple may retain a 60Hz refresh rate rather than bringing the 120Hz ProMotion technology used by the iPad Pro. That could disappoint buyers hoping the mini would become a compact Pro model, but OLED alone would represent a visible upgrade.

Reports have also pointed to an A19 Pro chip. That would give the smaller tablet more performance for games, creative apps, Apple Intelligence and longer-term software support. The current iPad mini already occupies an unusual position between a reading device and a compact professional tool. A stronger chip and OLED screen would push it further toward the second category.

Price may become the less attractive part of the update. Apple could raise the starting cost as display and memory expenses increase. Buyers interested mainly in portability may accept a higher price, but the iPad mini would need to avoid moving too close to the iPad Air.

The Entry-Level iPad May Stay Familiar

Apple’s least expensive iPad is expected to receive a more modest update in early 2027. The company reportedly plans to preserve the current design while replacing the processor with a newer chip.

That would fit the role of the entry-level model. Apple uses it for education, families, basic productivity, streaming, games and first-time tablet buyers. A dramatic redesign could increase the cost without improving the tasks most customers use it for.

The processor update could bring Apple Intelligence compatibility, depending on the chip and memory configuration Apple chooses. The current model’s position outside some advanced AI features creates an increasingly visible separation from the rest of the lineup.

A newer chip would also extend the useful life of the device. Entry-level iPads are often kept for several years, passed between family members or deployed in schools and businesses. Long software support can be more valuable in that segment than a thinner body or new camera arrangement.

Anyone considering the current base iPad should decide whether price or longevity has greater value. The current model remains suitable for ordinary use, particularly when discounted. Buyers who want the longest possible support window may prefer to wait.

iPad Air Could Receive the Larger Display Upgrade

The iPad Air is also expected to receive an update in 2027, with OLED display technology reportedly planned for the range. That would narrow one of the most obvious visual differences between the Air and the iPad Pro.

Apple currently positions the Air as the balanced choice: stronger than the entry model, less expensive than the Pro and available in 11-inch and 13-inch sizes. It supports Apple Pencil Pro and Magic Keyboard while offering M-series performance for demanding apps.

An OLED display would make that value proposition more aggressive. The Air could offer improved contrast and image quality without requiring buyers to move to the Pro tier. Apple would still have several ways to distinguish the Pro, including ProMotion, brighter displays, thinner hardware, advanced cameras and newer processors.

The processor is likely to receive another M-series upgrade as well, though the exact chip remains uncertain. For most users, the Air already has far more processing power than routine tablet work demands. The screen may provide the stronger reason to wait.

The risk for Apple is pricing. OLED panels could push the Air upward, especially in the 13-inch configuration. If the gap between Air and Pro becomes too narrow, buyers may move directly to the flagship. Apple will need to preserve a convincing middle tier.

iPad Pro May Focus on Power and Accessories

The next iPad Pro is reportedly planned for spring 2027. Apple may use a new M-series processor while leaving the current thin design largely intact.

That would make the Pro refresh more evolutionary than transformative. The current generation already includes OLED displays, high-end performance, Face ID, ProMotion and support for Apple Pencil Pro and Magic Keyboard.

Apple is also reportedly preparing two updated Apple Pencil models. Those accessories could arrive alongside the next iPad Pro, with changes potentially related to battery design and regulatory requirements.

The larger question is what additional processor power will do for the tablet. iPadOS 27 has expanded multitasking and window management, but buyers continue to evaluate the Pro against MacBook models at similar prices. A faster chip alone will not settle that comparison.

Apple may rely more heavily on AI, professional applications and accessory integration to justify the update. The Pro has become a platform for illustration, video editing, music production, 3D work and specialized enterprise apps. New hardware needs to strengthen those uses rather than simply win another benchmark.

Should Buyers Wait?

The answer depends on the model. Prospective iPad mini buyers have the strongest reason to pause because the reported fall update could introduce a substantially better display within months.

Entry-level buyers can still consider the current iPad when pricing is attractive. Its expected replacement appears focused on performance rather than design. Waiting becomes more sensible for anyone who wants Apple Intelligence support or maximum longevity.

The current iPad Air remains a capable option, particularly for users who need a tablet now. OLED would improve the experience, but a 2027 release leaves a longer wait. The same logic applies to the iPad Pro. Its successor may be faster, though the existing model already covers demanding work comfortably.

Apple’s gradual schedule could keep the iPad in the hardware conversation from fall through spring. It also means there will be no single perfect moment when every model is equally new.

The iPad mini may open the cycle because it has the most obvious opportunity for visible improvement. After that, Apple can use the base iPad for reach, the Air for broader OLED adoption and the Pro for its latest silicon and accessories.

The tablet lineup is not expected to change all at once. It may instead evolve model by model, giving buyers repeated reasons to reconsider which iPad fits their needs.

The post iPad Lineup Refresh Could Start This Fall appeared first on AppleMagazine.

Ao longo dos anos a Neuralink de Elon Musk tem partilhado casos de sucesso nos testes dos seus implantes neurais. Mas foi a chinesa Neuracle que aplicou o primeiro chip cerebral comercial.

The post China “finta” os Estados Unidos e implanta o primeiro chip cerebral comercial do mundo appeared first on Tek Notícias.

Descubra como o chip Jalapeno da OpenAI promete melhorar desempenho e reduzir custos em inteligência artificial.

O post OpenAI revela chip ‘Jalapeno’ para acelerar IA com alta eficiência energética apareceu primeiro em Blog do Edivaldo - Informações e Notícias sobre Linux.